BRAF V600

Under specific circumstances, CNB can provide an effective diagnostic approach for thyroid tumors. Moreover, in this case, we identified a novel TP53 intronic mutation that may drive the development of thyroid PRMS.

Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations...Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists.

Definitive diagnosis requires pathology, though sampling bias poses challenges. Advanced imaging (contrast-enhanced 3D T2-FLAIR MRI) and biomarkers (BRAF V600E, beta-catenin, p53, Ki-67) show promise in improving diagnosis, predicting recurrence, and guiding treatment.

Treatment similar to that of melanoma was commenced with pembrolizumab, which he completed without significant side-effects...Paediatric metastatic atypical DPN is not documented. Paediatric oncology supraspecialist MDT consensus was mandatory for management and support for our patient.

We present the largest dataset on melanoma BRAF status in England. These findings underscore the importance of incorporating BRAF testing into -early-stage melanoma care, ensuring early and accurate testing to guide treatment and improve understanding of patient prognosis.

Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.

The study provides a TT-focused prospective analysis still rare in pediatric oncology. The outcomes indicate satisfactory tolerance and promising efficacy of TT, prompting an update of current treatment standards for several pediatric cancers.

P1/2, N=161, Completed, Takeda | N=109 --> 161

Glioblastoma (GBM) remains associated with poor outcomes, with a median survival of 15-18 months despite maximal safe resection, radiotherapy, and temozolomide. CAR T-cell therapies are advancing toward bispecific and armored constructs with locoregional delivery, while oncolytic viruses such as DNX-2401 and PVSRIPO demonstrate potential for durable responses in select patients. Looking ahead, progress is likely to arise from biomarker-informed, multimodal regimens that integrate targeted agents, next-generation immunotherapies, and precision-guided strategies, while embedding translational endpoints into trial design to address the complex biology and therapeutic resistance of GBM.

P1, N=15, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2026

The analysis revealed an association between the BRAF V600E mutation and papillary thyroid cancer in patients exposed to radiation from nuclear testing at the former SNTS. These findings offer new prospects for targeted therapy and early diagnosis of malignant thyroid neoplasms. Following the closure of the test site, positive developments in public health have been observed: radiophobia has decreased and the population's quality of life has improved. Furthermore, the adoption of iodine prophylaxis legislation and the country's industrial growth have contributed to improved well-being and better epidemiological outcomes for thyroid cancer in subsequent generations.

The Myriapod NGS panel aids in the preoperative assessment of thyroid nodules. Its high negative predictive value may help avoid unnecessary surgery, whereas the detection of specific mutations strongly correlates with malignancy, thus informing surgical planning.